Diurnal Group has decided to put a hold on all activities relating to the US development of its adrenal drug Chronocort following a failure in a recently concluded phase 3 trial in adults with congenital adrenal hyperplasia (CAH).
US-based Revolution Medicines has acquired Warp Drive Bio for an undisclosed sum as part of its efforts to expand drug discovery portfolio.
HiFiBiO Therapeutics has acquired H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics.
Alliqua BioMedical has entered into a merger agreement with Adynxx to create a clinical-stage pharmaceutical firm, which will focus on development of therapies for pain and inflammation.
Carrick Therapeutics has acquired global licensing rights to develop and commercialize BTG’s ovarian cancer drug BTG945, which has been renamed as CT900.
Mundipharma, a global network of privately-owned independent associated companies, has acquired Spanish biosimilars development company Cinfa Biotech from Infarco for an undisclosed price.
Neurocrine Biosciences and Jnana Therapeutics have entered into a research collaboration to discover novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders.
New biopharmaceutical company Sitryx has been launched with $30m fundraising for the development of disease modifying therapeutics in immunometabolism.
Biopharmaceutical firm Arrowhead Pharmaceuticals has signed a license and collaboration agreement with Janssen Pharmaceuticals for the development and commercialization of hepatitis B virus (HBV) treatment, ARO-HBV.
Boston Pharmaceuticals has signed a licensing and equity agreement with Novartis for the worldwide rights to three of the latter's anti-infective candidates for the potential treatment of Gram-negative infections.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.